Q9Z0Y9
PR
Gene name |
Nr1h3 (Lxra) |
Protein name |
Oxysterols receptor LXR-alpha |
Names |
Liver X receptor alpha, Nuclear receptor subfamily 1 group H member 3 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:22259 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
4 structures for Q9Z0Y9
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2ACL | X-ray | 280 A | B/D/F/H | 203-445 | PDB |
| 3FAL | X-ray | 236 A | B/D | 200-445 | PDB |
| 3FC6 | X-ray | 206 A | B/D | 200-445 | PDB |
| AF-Q9Z0Y9-F1 | Predicted | AlphaFoldDB |
12 variants for Q9Z0Y9
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388573272 | 26 | Q>R | No | EVA | |
| rs16822021 | 50 | V>G | No | EVA | |
| rs3388568617 | 206 | P>VSDG* | No | EVA | |
| rs3388567693 | 208 | Q>E | No | EVA | |
| rs3388573218 | 208 | Q>P | No | EVA | |
| rs3388570023 | 320 | N>K | No | EVA | |
| rs3391880676 | 360 | I>L | No | EVA | |
| rs3388573322 | 371 | Q>H | No | EVA | |
| rs3388573241 | 393 | I>F | No | EVA | |
| rs3388573233 | 397 | H>N | No | EVA | |
| rs3388567688 | 438 | S>T | No | EVA | |
| rs3388561160 | 443 | V>A | No | EVA |
No associated diseases with Q9Z0Y9
11 regional properties for Q9Z0Y9
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | B-box-type zinc finger | 81 - 122 | IPR000315 |
| domain | Zinc finger, RING-type | 14 - 57 | IPR001841 |
| domain | B30.2/SPRY domain | 271 - 475 | IPR001870 |
| domain | SPRY domain | 342 - 473 | IPR003877 |
| domain | Butyrophylin-like, SPRY domain | 287 - 304 | IPR003879-1 |
| domain | Butyrophylin-like, SPRY domain | 327 - 351 | IPR003879-2 |
| domain | Butyrophylin-like, SPRY domain | 357 - 370 | IPR003879-3 |
| domain | Butyrophylin-like, SPRY domain | 404 - 428 | IPR003879-4 |
| domain | SPRY-associated | 288 - 341 | IPR006574 |
| conserved_site | Zinc finger, RING-type, conserved site | 29 - 38 | IPR017907 |
| domain | Zinc finger, RING-type, eukaryotic | 14 - 54 | IPR027370 |
7 GO annotations of cellular component
| Name | Definition |
|---|---|
| chromatin | The ordered and organized complex of DNA, protein, and sometimes RNA, that forms the chromosome. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| RNA polymerase II transcription regulator complex | A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase II. |
11 GO annotations of molecular function
| Name | Definition |
|---|---|
| chromatin DNA binding | Binding to DNA that is assembled into chromatin. |
| DNA-binding transcription activator activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that activates or increases transcription of specific gene sets transcribed by RNA polymerase II. |
| DNA-binding transcription factor activity | A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons. |
| nuclear receptor activity | A DNA-binding transcription factor activity regulated by binding to a ligand that modulates the transcription of specific gene sets transcribed by RNA polymerase II. Nuclear receptor ligands are usually lipid-based (such as a steroid hormone) and the binding of the ligand to its receptor often occurs in the cytoplasm, which leads to its tranlocation to the nucleus. |
| nuclear retinoid X receptor binding | Binding to a nuclear retinoid X receptor. |
| protein-containing complex binding | Binding to a macromolecular complex. |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. |
| sequence-specific DNA binding | Binding to DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding. |
| sterol response element binding | Binding to a sterol response element (SRE), a nonpalindromic sequence found in the promoters of genes involved in lipid metabolism. |
| transcription cis-regulatory region binding | Binding to a specific sequence of DNA that is part of a regulatory region that controls transcription of that section of the DNA. The transcribed region might be described as a gene, cistron, or operon. |
| zinc ion binding | Binding to a zinc ion (Zn). |
35 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic cell clearance | The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte. |
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| cellular lipid metabolic process | The chemical reactions and pathways involving lipids, as carried out by individual cells. |
| cellular response to lipopolysaccharide | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. |
| cholesterol homeostasis | Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell. |
| fatty acid biosynthetic process | The chemical reactions and pathways resulting in the formation of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes. |
| hormone-mediated signaling pathway | The series of molecular signals mediated by the detection of a hormone. |
| lipid homeostasis | Any process involved in the maintenance of an internal steady state of lipid within an organism or cell. |
| mRNA transcription by RNA polymerase II | The cellular synthesis of messenger RNA (mRNA) from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter. |
| negative regulation of cholesterol storage | Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. |
| negative regulation of cold-induced thermogenesis | Any process that stops, prevents, or reduces the rate of cold-induced thermogenesis. |
| negative regulation of DNA-templated transcription | Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. |
| negative regulation of inflammatory response | Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response. |
| negative regulation of lipid transport | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of macrophage activation | Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage activation. |
| negative regulation of pancreatic juice secretion | Any process that decreases the rate, frequency or extent of pancreatic juice secretion, the regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine. |
| negative regulation of pinocytosis | Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes. |
| negative regulation of proteolysis | Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein. |
| negative regulation of response to endoplasmic reticulum stress | Any process that stops, prevents or reduces the frequency, rate or extent of a response to endoplasmic reticulum stress. |
| negative regulation of secretion of lysosomal enzymes | Any process that decreases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell. |
| negative regulation of transcription by RNA polymerase II | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| phosphatidylcholine acyl-chain remodeling | Remodeling the acyl chains of phosphatidylcholine, through sequential deacylation and re-acylation reactions, to generate phosphatidylcholine containing different types of fatty acid acyl chains. |
| positive regulation of cholesterol efflux | Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. |
| positive regulation of cholesterol transport | Any process that activates or increases the frequency, rate or extent of the directed movement of cholesterol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of fatty acid biosynthetic process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids. |
| positive regulation of lipoprotein lipase activity | Any process that activates or increases the activity of the enzyme lipoprotein lipase. |
| positive regulation of protein metabolic process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein. |
| positive regulation of toll-like receptor 4 signaling pathway | Any process that activates or increases the frequency, rate, or extent of toll-like receptor 4 signaling pathway. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| positive regulation of triglyceride biosynthetic process | Any process that increases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol. |
| regulation of DNA-templated transcription | Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. |
| response to progesterone | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a progesterone stimulus. |
| sterol homeostasis | Any process involved in the maintenance of an internal steady state of sterol within an organism or cell. |
| triglyceride homeostasis | Any process involved in the maintenance of an internal steady state of triglyceride within an organism or cell. |
28 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9TTR7 | NR2F2 | COUP transcription factor 2 | Bos taurus (Bovine) | PR |
| O18971 | PPARG | Peroxisome proliferator-activated receptor gamma | Bos taurus (Bovine) | PR |
| Q90733 | NR2F2 | COUP transcription factor 2 | Gallus gallus (Chicken) | PR |
| P68306 | THRB | Thyroid hormone receptor beta | Gallus gallus (Chicken) | PR |
| A7X8B3 | PGR | Progesterone receptor | Pan troglodytes (Chimpanzee) | SS |
| P37231 | PPARG | Peroxisome proliferator-activated receptor gamma | Homo sapiens (Human) | PR |
| P10588 | NR2F6 | Nuclear receptor subfamily 2 group F member 6 | Homo sapiens (Human) | PR |
| P06401 | PGR | Progesterone receptor | Homo sapiens (Human) | EV |
| P10589 | NR2F1 | COUP transcription factor 1 | Homo sapiens (Human) | PR |
| O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (Human) | PR |
| P24468 | NR2F2 | COUP transcription factor 2 | Homo sapiens (Human) | PR |
| P49116 | NR2C2 | Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (Human) | PR |
| P43136 | Nr2f6 | Nuclear receptor subfamily 2 group F member 6 | Mus musculus (Mouse) | PR |
| P43135 | Nr2f2 | COUP transcription factor 2 | Mus musculus (Mouse) | PR |
| Q00175 | Pgr | Progesterone receptor | Mus musculus (Mouse) | SS |
| P35396 | Ppard | Peroxisome proliferator-activated receptor delta | Mus musculus (Mouse) | PR |
| O62807 | PPARG | Peroxisome proliferator-activated receptor gamma | Sus scrofa (Pig) | PR |
| O09018 | Nr2f2 | COUP transcription factor 2 | Rattus norvegicus (Rat) | PR |
| Q63449 | Pgr | Progesterone receptor | Rattus norvegicus (Rat) | SS |
| Q8SQ01 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Macaca mulatta (Rhesus macaque) | PR |
| G5EFF5 | daf-12 | Nuclear hormone receptor family member daf-12 | Caenorhabditis elegans | PR |
| O45460 | nhr-54 | Nuclear hormone receptor family member nhr-54 | Caenorhabditis elegans | PR |
| Q20765 | nhr-7 | Nuclear hormone receptor family member nhr-7 | Caenorhabditis elegans | PR |
| Q21006 | nhr-34 | Nuclear hormone receptor family member nhr-34 | Caenorhabditis elegans | PR |
| O17928 | nhr-52 | Nuclear hormone receptor family member nhr-52 | Caenorhabditis elegans | PR |
| Q21878 | nhr-1 | Nuclear hormone receptor family member nhr-1 | Caenorhabditis elegans | PR |
| O18141 | nhr-79 | Nuclear hormone receptor family member nhr-79 | Caenorhabditis elegans | PR |
| Q6PH18 | nr2f1b | Nuclear receptor subfamily 2 group F member 1-B | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSLWLEASMP | DVSPDSATEL | WKTEPQDAGD | QGGNTCILRE | EARMPQSTGV | ALGIGLESAE |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PTALLPRAET | LPEPTELRPQ | KRKKGPAPKM | LGNELCSVCG | DKASGFHYNV | LSCEGCKGFF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| RRSVIKGARY | VCHSGGHCPM | DTYMRRKCQE | CRLRKCRQAG | MREECVLSEE | QIRLKKLKRQ |
| 190 | 200 | 210 | 220 | 230 | 240 |
| EEEQAQATSV | SPRVSSPPQV | LPQLSPEQLG | MIEKLVAAQQ | QCNRRSFSDR | LRVTPWPIAP |
| 250 | 260 | 270 | 280 | 290 | 300 |
| DPQSREARQQ | RFAHFTELAI | VSVQEIVDFA | KQLPGFLQLS | REDQIALLKT | SAIEVMLLET |
| 310 | 320 | 330 | 340 | 350 | 360 |
| SRRYNPGSES | ITFLKDFSYN | REDFAKAGLQ | VEFINPIFEF | SRAMNELQLN | DAEFALLIAI |
| 370 | 380 | 390 | 400 | 410 | 420 |
| SIFSADRPNV | QDQLQVERLQ | HTYVEALHAY | VSINHPHDPL | MFPRMLMKLV | SLRTLSSVHS |
| 430 | 440 | ||||
| EQVFALRLQD | KKLPPLLSEI | WDVHE |